Pfizer Inc
(MIL:1PFE)
€
24.625
-0.16 (-0.65%)
Market Cap: 138.78 Bil
Enterprise Value: 192.52 Bil
PE Ratio: 34.89
PB Ratio: 1.59
GF Score: 64/100 Pfizer Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 04:15PM GMT
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Great. Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley, and we're very pleased to be hosting Pfizer today. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Today from the company, we have Angela Hwang, who is CCO and President of the Biopharma segment at Pfizer; and Suneet Varma, who is Global Oncology and U.S. President, also within the Biopharma Group.
Thanks so much both for joining us today. Really appreciate the time.
Suneet Varma
Pfizer Inc. - Global & U.S. President of Oncology
Thank you.
Questions & Answers
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
I thought maybe to start off, a question we get a lot from investors is just the 6% revenue growth guidance that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot